John Sterling is the Editor in Chief of Genetic Engineering & Biotechnology News. With a focus on biotechnology and precision medicine, John's articles provide insights into the latest advancements and challenges in the field. His work has also been featured in publications such as Inside Precision Medicine and Upstate Business Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John Sterling's articles primarily focus on scientific and healthcare & pharmaceutical topics, with a specific emphasis on biopharmaceutical manufacturing, bioprocessing, cell therapy, drug discovery, and biotechnology. His coverage attributes show a strong reliance on press releases and data citations.
To effectively reach out to John Sterling for potential coverage or commentary opportunities related to the mentioned themes and topics, consider offering detailed insights supported by credible data from reputable sources within the relevant industries. Additionally, providing access to newsworthy announcements or industry-specific developments may enhance the appeal of your pitch when approaching him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Sterling
The Nicotiana benthamiana tobacco plant is increasingly used for the production of high-value, biologically active molecules. [Wiki Commons]
By: John Sterling
Credit: Reptile8488/Getty Images Cambrex, a CDMO, signed an agreement with Eli Lilly to deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.
By: John Sterling
The World Health Organization (WHO) is opening its call for expression of interest (EOI) to join as a Regional Biomanufacturing Training Center under the WHO Biomanufacturing Workforce Training Initiative
By: John Sterling
Credit: Bingdian/Getty Images LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected
By: John Sterling
Animal imaging studies also confirmed the effects of the gene therapy were limited to cancer tissue and were undetectable in normal tissue. Results further suggested that attaching the monoclonal antibody had the added benefit of inducing an immune response against cancer cells in the tumor microenvironment.
By: John Sterling
“This work offers a promising platform for the development of advanced drug delivery systems and other biomedical applications.”
By: John Sterling
Emily Han, a doctoral student in the Mitchell Lab at the University of Pennsylvania, developed a method for delivering lipid nanoparticles to neurons. [Bella Ciervo]
By: John Sterling
Experiments in mouse models showed the gene therapy strategy significantly reduced the tumor burden compared to untreated animals in two fast-growing, difficult-to-treat cancers.
By: John Sterling
From left: Qiuyue Nie, PhD, and Maria Zotova work in the lab designed for culturing fungi at the University of Pennsylvania School of Engineering and Applied Science. [Bella Ciervo]
By: John Sterling
Credit: Gri-spb/Getty Images Scinai Immunotherapeutics, which focuses on developing inflammation and immunology biological products and
(833) 317-6278 
